SEGA
MCID: SBP001
MIFTS: 51

Subependymal Giant Cell Astrocytoma (SEGA)

Categories: Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Subependymal Giant Cell Astrocytoma

MalaCards integrated aliases for Subependymal Giant Cell Astrocytoma:

Name: Subependymal Giant Cell Astrocytoma 12 53 59 37 15 73
Sega 12 53 59
Astrocytoma Subependymal Giant Cell 55
Subependymal Giant-Cell Astrocytoma 6

Classifications:

Orphanet: 59  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:5077
MeSH 44 D001254
NCIt 50 C3696
SNOMED-CT 68 1586004
Orphanet 59 ORPHA251618
UMLS via Orphanet 74 C0205768
ICD10 via Orphanet 34 D43.2
KEGG 37 H01692
UMLS 73 C0205768

Summaries for Subependymal Giant Cell Astrocytoma

MalaCards based summary : Subependymal Giant Cell Astrocytoma, also known as sega, is related to tuberous sclerosis 1 and tuberous sclerosis, and has symptoms including seizures and headache. An important gene associated with Subependymal Giant Cell Astrocytoma is TSC2 (TSC Complex Subunit 2), and among its related pathways/superpathways are mTOR signaling pathway and mTOR signaling pathway (KEGG). The drugs Afinitor and Everolimus have been mentioned in the context of this disorder. Affiliated tissues include brain, lung and liver, and related phenotypes are behavior/neurological and nervous system

Wikipedia : 76 Subependymal giant cell astrocytoma (SEGA, SGCA, or SGCT) is a low-grade astrocytic brain tumor... more...

Related Diseases for Subependymal Giant Cell Astrocytoma

Diseases related to Subependymal Giant Cell Astrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 213)
# Related Disease Score Top Affiliating Genes
1 tuberous sclerosis 1 31.4 MTOR TSC1 TSC2
2 tuberous sclerosis 30.9 GFAP MTOR S100B SYP TSC1 TSC2
3 angiomyolipoma 30.7 MTOR TSC1 TSC2
4 kidney angiomyolipoma 30.6 MTOR TSC1 TSC2
5 giant cell glioblastoma 30.5 GFAP SYP
6 gemistocytic astrocytoma 30.4 GFAP S100B
7 obstructive hydrocephalus 30.3 GFAP SYP
8 hydrocephalus 30.1 ENO2 GFAP NES SYP
9 astrocytoma 11.2
10 epilepsy 10.4
11 neuroblastoma 10.3
12 ileum cancer 10.3 ENO2 GFAP
13 scrapie 10.3 ENO2 GFAP
14 dysgerminoma of ovary 10.3 ENO2 GFAP
15 juvenile pilocytic astrocytoma 10.3 ENO2 GFAP
16 alexander disease 10.2 GFAP MTOR
17 primitive neuroectodermal tumor of the cervix uteri 10.2 ENO2 GFAP
18 melanotic medulloblastoma 10.2 ENO2 GFAP
19 meningioma, radiation-induced 10.2 GFAP S100B
20 myoepithelioma 10.2 GFAP S100B
21 pilomatrixoma 10.2 ENO2 S100B
22 cerebellar medulloblastoma 10.2 ENO2 GFAP
23 spondylosis 10.2 ENO2 S100B
24 extraosseous ewing's sarcoma 10.2 ENO2 S100B
25 meningeal melanocytoma 10.2 ENO2 S100B
26 acute mountain sickness 10.2 ENO2 S100B
27 plexiform schwannoma 10.2 ENO2 GFAP
28 pineoblastoma 10.2 GFAP SYP
29 atypical teratoid rhabdoid tumor 10.2 GFAP SYP
30 cerebellopontine angle tumor 10.2 GFAP SYP
31 pilomyxoid astrocytoma 10.2 GFAP SYP
32 binswanger's disease 10.2 GFAP SYP
33 chondrosarcoma, extraskeletal myxoid 10.2 ENO2 SYP
34 connective tissue benign neoplasm 10.2 ENO2 SYP
35 microcystic meningioma 10.2 ENO2 GFAP
36 malignant pheochromocytoma 10.2 ENO2 SYP
37 mixed cell type cancer 10.2 ENO2 SYP
38 adrenal rest tumor 10.2 ENO2 SYP
39 glomus tumor 10.2 ENO2 SYP
40 cranial nerve malignant neoplasm 10.2 ENO2 SYP
41 intraocular retinoblastoma 10.2 ENO2 SYP
42 pineal parenchymal tumor of intermediate differentiation 10.2 ENO2 SYP
43 basaloid squamous cell carcinoma 10.2 ENO2 SYP
44 cervix small cell carcinoma 10.2 ENO2 SYP
45 mixed ductal-endocrine carcinoma 10.2 ENO2 SYP
46 carcinoid syndrome 10.2 ENO2 SYP
47 granulosa cell tumor of the ovary 10.2 ENO2 SYP
48 corneal dystrophy, fleck 10.2 TSC1 TSC2
49 congenital heart defects, hamartomas of tongue, and polysyndactyly 10.2 TSC1 TSC2
50 bednar tumor 10.2 ENO2 S100B

Graphical network of the top 20 diseases related to Subependymal Giant Cell Astrocytoma:



Diseases related to Subependymal Giant Cell Astrocytoma

Symptoms & Phenotypes for Subependymal Giant Cell Astrocytoma

UMLS symptoms related to Subependymal Giant Cell Astrocytoma:


seizures, headache

MGI Mouse Phenotypes related to Subependymal Giant Cell Astrocytoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.76 ENO2 GFAP MTOR NKX2-1 S100B SYP
2 nervous system MP:0003631 9.5 ENO2 GFAP MTOR NKX2-1 SYP TSC1
3 normal MP:0002873 9.1 GFAP MTOR NKX2-1 S100B SYP TSC2

Drugs & Therapeutics for Subependymal Giant Cell Astrocytoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Afinitor 18 49 EVEROLIMUS Novartis March 2009

Drugs for Subependymal Giant Cell Astrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 145)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
2
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
4 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1
5 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
6 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
7 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
8 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
9 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
11
Cisplatin Approved Phase 3,Phase 1 15663-27-1 2767 441203 84093
12
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 1177-87-3
13
Ondansetron Approved Phase 3 99614-02-5 4595
14
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
15
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
16
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
17
Cyproheptadine Approved Phase 3 129-03-3 2913
18 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
19 Dermatologic Agents Phase 3,Phase 1
20 Cola Phase 3
21 Central Nervous System Depressants Phase 3
22 Adjuvants, Anesthesia Phase 3
23 Liver Extracts Phase 3,Phase 1,Phase 2
24 Anesthetics, Intravenous Phase 3
25 Analgesics, Opioid Phase 3
26 Peripheral Nervous System Agents Phase 3,Phase 1
27 Anesthetics, General Phase 3
28 Analgesics Phase 3,Phase 1
29 Narcotics Phase 3
30 Anesthetics Phase 3
31 Gastrointestinal Agents Phase 3,Phase 1,Not Applicable
32 Antiemetics Phase 3,Phase 1
33 Autonomic Agents Phase 3,Phase 1
34 BB 1101 Phase 3,Phase 2,Phase 1
35 Emetics Phase 3
36 Neurotransmitter Agents Phase 3,Early Phase 1,Not Applicable
37 Serotonin Agents Phase 3
38 Anti-Allergic Agents Phase 3
39 Serotonin Antagonists Phase 3
40 Histamine H1 Antagonists Phase 3
41
Histamine Phosphate Phase 3 51-74-1 65513
42 Antipruritics Phase 3
43 Histamine Antagonists Phase 3
44
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
45
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
46
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
47
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
48
Bevacizumab Approved, Investigational Phase 2 216974-75-3
49
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
50
Armodafinil Approved, Investigational Phase 2 112111-43-0

Interventional clinical trials:

(show top 50) (show all 56)
# Name Status NCT ID Phase Drugs
1 Long-term Follow-up for Growth and Development of Pediatric Patients From CRAD001M2301 Active, not recruiting NCT02338609 Phase 4 Everolimus;Envirolimus drug class as prescribed by Physician
2 Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1) Completed NCT00789828 Phase 3 Everolimus;Placebo
3 Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) Completed NCT00790400 Phase 3 Everolimus (RAD001);Everolimus Placebo
4 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
5 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
6 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
7 Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer Unknown status NCT02188550 Phase 2 everolimus and letrozole
8 Bevacizumab in Recurrent Grade II and III Glioma Unknown status NCT01164189 Phase 2 Temozolomide
9 Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex Completed NCT00411619 Phase 1, Phase 2 Everolimus
10 Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma Completed NCT00112736 Phase 1, Phase 2 erlotinib;temsirolimus
11 Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma Completed NCT01462695 Phase 2 Sunitinib Malate
12 Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors Completed NCT01032200 Phase 2 Armodafinil
13 Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors Completed NCT00541138 Phase 2 carboplatin;tamoxifen citrate;topotecan hydrochloride
14 Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma Completed NCT00498927 Phase 2 temozolomide
15 A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD Recruiting NCT02451696 Phase 2 Everolimus
16 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
17 Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Active, not recruiting NCT00553150 Phase 1, Phase 2 everolimus;temozolomide
18 Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Active, not recruiting NCT00788125 Phase 1, Phase 2 carboplatin;dasatinib;etoposide phosphate;ifosfamide
19 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors Unknown status NCT00002647 Phase 1 verteporfin
20 Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas Unknown status NCT00083096 Phase 1 lonafarnib;temozolomide
21 Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma Unknown status NCT00360854 Phase 1 erlotinib hydrochloride
22 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
23 Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors Completed NCT01076530 Phase 1 vorinostat;temozolomide
24 Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma Completed NCT00994500 Phase 1 vorinostat;bortezomib
25 ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors Completed NCT00946335 Phase 1 veliparib;temozolomide
26 AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors Completed NCT00326664 Phase 1 Cediranib Maleate
27 Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors Completed NCT00100880 Phase 1 lenalidomide
28 Cilengitide in Treating Children With Refractory Primary Brain Tumors Completed NCT00063973 Phase 1 cilengitide
29 Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors Completed NCT00052780 Phase 1 O6-benzylguanine;temozolomide
30 Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma Completed NCT00730613 Phase 1
31 Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment Completed NCT00544284 Phase 1 bortezomib;temozolomide
32 Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma Completed NCT00509431 Phase 1 Erlotinib + Sirolimus
33 Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers Completed NCT00498979 Phase 1 cisplatin;sodium stibogluconate;dacarbazine;vinblastine
34 Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma Completed NCT00401024 Phase 1 imatinib mesylate
35 Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma Completed NCT01273090 Phase 1 imetelstat sodium
36 PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors Completed NCT01158300 Phase 1 VEGF inhibitor PTC299
37 Enzastaurin in Treating Young Patients With Refractory Primary CNS Tumors Completed NCT00503724 Phase 1 enzastaurin hydrochloride
38 Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors Completed NCT00138216 Phase 1 irinotecan hydrochloride;temozolomide;vincristine sulfate
39 Phase I/Ib Dose Escalation & Biomarker Study of Ceritinib (LDK378) + Everolimus for Locally Advanced or Metastatic Solid Tumors With an Expansion in Non-Small Cell Lung Cancer (NSCLC) Characterized by Abnormalities in Anaplastic Lymphoma Kinase (ALK) Expression Recruiting NCT02321501 Phase 1 Ceritinib (LDK378);Ceritinib (LDK378) 750 mg;Everolimus
40 A Phase 1 Trial of Vandetanib (a Multi-kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer Recruiting NCT01582191 Phase 1 Vandetanib;Everolimus
41 Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer Active, not recruiting NCT01087554 Phase 1 Sirolimus;Vorinostat;Everolimus;Temsirolimus
42 Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas Active, not recruiting NCT02186509 Phase 1 Alisertib
43 Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia Terminated NCT01088763 Phase 1 gamma-secretase/Notch signalling pathway inhibitor RO4929097;dexamethasone
44 Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors Terminated NCT00112619 Phase 1 topotecan hydrochloride
45 Study of Blood and Cheek Cell Samples From Patients With Glioma Completed NCT01009307
46 Study of Blood Samples and Risk of Infection in Patients With Newly Diagnosed Malignant Supratentorial Astrocytoma Completed NCT00999622
47 Study of Tissue Samples From Patients With Glioma or Other Brain Tumors Completed NCT00967200
48 Metabolic Syndrome in Childhood Cancer Survivors Completed NCT00920738
49 Changes in Semen or Sperm Caused by Temozolomide in Patients With Newly Diagnosed, Progressive, or Recurrent Primary Malignant Brain Tumors Completed NCT00499798
50 Donepezil in Treating Young Patients With Primary Brain Tumors Previously Treated With Radiation Therapy to the Brain Completed NCT00452868 Early Phase 1 Donepezil

Search NIH Clinical Center for Subependymal Giant Cell Astrocytoma

Genetic Tests for Subependymal Giant Cell Astrocytoma

Anatomical Context for Subependymal Giant Cell Astrocytoma

MalaCards organs/tissues related to Subependymal Giant Cell Astrocytoma:

41
Brain, Lung, Liver, Spinal Cord, Kidney, Bone, Testis

Publications for Subependymal Giant Cell Astrocytoma

Articles related to Subependymal Giant Cell Astrocytoma:

(show top 50) (show all 149)
# Title Authors Year
1
Trapped ventricle after laser ablation of a subependymal giant cell astrocytoma complicated by intraventricular gadolinium extravasation: case report. ( 29451453 )
2018
2
Efficacy and safety of everolimus in patients younger than 12a8^months with congenital subependymal giant cell astrocytoma. ( 29395661 )
2018
3
Atypical subependymal giant cell astrocytoma and neonatal tuberous sclerosis. ( 29555882 )
2018
4
Effect of everolimus on skin lesions in patients treated for subependymal giant cell astrocytoma and renal angiomyolipoma: final 4-year results from the randomised EXIST-1 and EXIST-2 studies. ( 29569806 )
2018
5
The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma. ( 28993887 )
2018
6
Subependymal giant cell astrocytoma-like astrocytoma: a neoplasm with a distinct phenotype and frequent neurofibromatosis type-1-association. ( 29973652 )
2018
7
Everolimus compliance and persistence among tuberous sclerosis complex patients with renal angiomyolipoma or subependymal giant cell astrocytoma. ( 30550347 )
2018
8
The level of microRNA 21 is upregulated by rapamycin in serum of tuberous sclerosis complex patients and subependymal giant cell astrocytoma (SEGA)-derived cell cultures. ( 30509037 )
2018
9
Subependymal Giant Cell Astrocytoma: A Surveillance, Epidemiology, and End Results Program-Based Analysis from 2004 to 2013. ( 29966782 )
2018
10
Subependymal Giant Cell Astrocytoma: Associated Hyperproteinorrhachia Causing Shunt Failures and Nonobstructive Hydrocephalus - Report of Successful Treatment with Long-term Follow-up. ( 29114301 )
2017
11
Unique findings of subependymal giant cell astrocytoma within cortical tubers in patients with tuberous sclerosis complex: a histopathological evaluation. ( 28074282 )
2017
12
Subependymal Giant Cell Astrocytoma Presenting with Tumoral Bleeding: A Case Report. ( 28516078 )
2017
13
Acute Management of Symptomatic Subependymal Giant Cell Astrocytoma With Everolimus. ( 28511812 )
2017
14
Presurgical Administration of mTOR Inhibitors in Patients with Large Subependymal Giant Cell Astrocytoma Associated with Tuberous Sclerosis Complex. ( 28866062 )
2017
15
What are the true volumes of SEGA tumors? Reliability of planimetric and popular semi-automated image segmentation methods. ( 28321524 )
2017
16
Screening for frailty in community-dwelling elderly subjects: Predictive validity of the modified SEGA instrument. ( 28822918 )
2017
17
Response to: S. Sega-Jazbec et al.: "Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis" Multiple Sclerosis and Related Disorders 2017. ( 29055453 )
2017
18
Role of mTOR signaling pathway in the pathogenesis of subependymal giant cell astrocytoma - A study of 28 cases. ( 27625244 )
2016
19
Maintenance therapy with everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis (the EMINENTS study). ( 27860334 )
2016
20
Imaging Manifestations of a Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis. ( 26942030 )
2016
21
Subependymal giant cell astrocytoma (SEGA): a case report and review of the literature. ( 26861567 )
2016
22
Intraoperative Squash Cytologic Features of Subependymal Giant Cell Astrocytoma. ( 27013816 )
2016
23
Mammalian Target of Rapamycin Inhibitor Induced Complete Remission of a Recurrent Subependymal Giant Cell Astrocytoma in a Patient Without Features of Tuberous Sclerosis Complex. ( 26929034 )
2016
24
Subependymal giant cell astrocytoma in a genetically negative tuberous sclerosis complex adult: Case report. ( 27690251 )
2016
25
Thyroid transcription factor-1 distinguishes subependymal giant cell astrocytoma from its mimics and supports its cell origin from the progenitor cells in the medial ganglionic eminence. ( 27910945 )
2016
26
EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex. ( 27502586 )
2016
27
Laser interstitial thermal therapy for subependymal giant cell astrocytoma: technical case report. ( 27690646 )
2016
28
Variability of Dose and Level of Sirolimus in a Patient With Tuberous Sclerosis Complex and Subependymal Giant Cell Astrocytoma. ( 27082208 )
2016
29
Subependymal giant cell astrocytoma: a lesion with activated mTOR pathway and constant expression of glutamine synthetase. ( 27390104 )
2016
30
Association between the growth rate of subependymal giant cell astrocytoma and age in patients with tuberous sclerosis complex. ( 26552385 )
2016
31
Retraction Note to: Subependymal giant cell astrocytoma: current concepts, management, and future directions. ( 26922080 )
2016
32
Pathological Findings of a Subependymal Giant Cell Astrocytoma Following Treatment With Rapamycin. ( 26173783 )
2015
33
Subependymal giant cell astrocytoma in the absence of tuberous sclerosis complex: case report. ( 25978531 )
2015
34
Dose-level response rates of mTor inhibition in tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA). ( 25929843 )
2015
35
Natural History and Current Treatment Options for Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis Complex. ( 26706014 )
2015
36
The clinical characteristics of subependymal giant cell astrocytoma: five cases. ( 25977907 )
2015
37
Erk activation as a possible mechanism of transformation of subependymal nodule into subependymal giant cell astrocytoma. ( 25909870 )
2015
38
Direct medical costs for patients with tuberous sclerosis complex and surgical resection of subependymal giant cell astrocytoma: a US national cohort study. ( 25525770 )
2015
39
Everolimus for subependymal giant cell astrocytoma: 5-year final analysis. ( 26381530 )
2015
40
Thyroid transcription factor-1 and epithelial membrane antigen expression in four cases of subependymal giant cell astrocytoma. ( 25195621 )
2014
41
Everolimus Treatment for an Early Infantile Subependymal Giant Cell Astrocytoma With Tuberous Sclerosis Complex. ( 25143481 )
2014
42
Surgical treatment of subependymal giant cell astrocytoma in tuberous sclerosis complex patients. ( 24507694 )
2014
43
Subependymal giant cell astrocytoma: current concepts, management, and future directions. ( 24549759 )
2014
44
Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. ( 25456370 )
2014
45
An unusually aggressive clinical behavior in a case of atypical subependymal giant cell astrocytoma. ( 25387628 )
2014
46
The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1. ( 24729041 )
2014
47
The outcome of surgical management of subependymal giant cell astrocytoma in tuberous sclerosis complex. ( 23183057 )
2013
48
Subependymal giant cell astrocytoma associated with tuberous sclerosis presenting with intratumoral bleeding. Case report and review of literature. ( 23138436 )
2013
49
Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): Clinical recommendations. ( 23391693 )
2013
50
Resection of subependymal giant cell astrocytoma guided by intraoperative magnetic resonance imaging and neuronavigation. ( 23397586 )
2013

Variations for Subependymal Giant Cell Astrocytoma

ClinVar genetic disease variations for Subependymal Giant Cell Astrocytoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 CACNA1A NM_001127221.1(CACNA1A): c.2585_2602del18 (p.Gln862_Asp867del) deletion Uncertain significance rs767951499 GRCh37 Chromosome 19, 13409848: 13409865
2 CACNA1A NM_001127221.1(CACNA1A): c.2585_2602del18 (p.Gln862_Asp867del) deletion Uncertain significance rs767951499 GRCh38 Chromosome 19, 13299034: 13299051

Expression for Subependymal Giant Cell Astrocytoma

Search GEO for disease gene expression data for Subependymal Giant Cell Astrocytoma.

Pathways for Subependymal Giant Cell Astrocytoma

Pathways related to Subependymal Giant Cell Astrocytoma according to KEGG:

37
# Name Kegg Source Accession
1 mTOR signaling pathway hsa04150

Pathways related to Subependymal Giant Cell Astrocytoma according to GeneCards Suite gene sharing:

(show all 28)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.27 MTOR TSC1 TSC2
2
Show member pathways
12.21 MTOR TSC1 TSC2
3
Show member pathways
12.19 MTOR TSC1 TSC2
4
Show member pathways
12.17 MTOR TSC1 TSC2
5
Show member pathways
12.16 MTOR TSC1 TSC2
6
Show member pathways
12.07 MTOR TSC1 TSC2
7 12.03 MTOR TSC1 TSC2
8
Show member pathways
11.98 MTOR TSC1 TSC2
9
Show member pathways
11.96 MTOR TSC1 TSC2
10 11.92 MTOR TSC1 TSC2
11 11.89 MTOR TSC1 TSC2
12 11.89 ENO2 GFAP NKX2-1 S100B SYP
13 11.87 MTOR TSC1 TSC2
14
Show member pathways
11.85 MTOR TSC1 TSC2
15
Show member pathways
11.83 MTOR TSC1 TSC2
16 11.74 MTOR TSC1 TSC2
17 11.65 MTOR TSC1 TSC2
18 11.51 MTOR TSC1 TSC2
19 11.33 MTOR TSC1 TSC2
20 11.31 TSC1 TSC2
21 11.3 MTOR TSC2
22 11.22 MTOR TSC1 TSC2
23 11.07 MTOR TSC2
24 11.06 MTOR TSC1 TSC2
25 11.01 MTOR TSC2
26 10.86 MTOR TSC1 TSC2
27 10.82 GFAP NES S100B SYP
28 10.78 MTOR TSC1

GO Terms for Subependymal Giant Cell Astrocytoma

Cellular components related to Subependymal Giant Cell Astrocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 TSC1-TSC2 complex GO:0033596 8.62 TSC1 TSC2

Biological processes related to Subependymal Giant Cell Astrocytoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 brain development GO:0007420 9.65 MTOR NES NKX2-1
2 long-term synaptic potentiation GO:0060291 9.49 GFAP S100B
3 negative regulation of TOR signaling GO:0032007 9.46 TSC1 TSC2
4 negative regulation of insulin receptor signaling pathway GO:0046627 9.43 TSC1 TSC2
5 positive regulation of macroautophagy GO:0016239 9.4 TSC1 TSC2
6 regulation of protein kinase activity GO:0045859 9.37 MTOR TSC1
7 regulation of neuronal synaptic plasticity GO:0048168 9.32 S100B SYP
8 positive regulation of glial cell proliferation GO:0060252 9.26 GFAP MTOR
9 negative regulation of macroautophagy GO:0016242 9.16 MTOR TSC1
10 anoikis GO:0043276 8.96 MTOR TSC2
11 negative regulation of cell size GO:0045792 8.62 MTOR TSC1

Molecular functions related to Subependymal Giant Cell Astrocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Hsp90 protein binding GO:0051879 8.62 TSC1 TSC2

Sources for Subependymal Giant Cell Astrocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....